Statins and the autonomic nervous system

Clinical Science

Volumn 126, Issue 5, 2014, Pages 401-415

  Millar, Philip J ^a   Floras, John S ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Blood pressure; Nitric oxide; Oxidative stress; Statin; Sympathetic nervous system

Indexed keywords

AMLODIPINE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARRHYTHMOGENESIS; AUTONOMIC NERVOUS SYSTEM; BRAIN REGION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; HEART FAILURE; HEART INFARCTION; HEART RATE VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MUSCLE SYMPATHETIC NERVE ACTIVITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SUDDEN CARDIAC DEATH; TREATMENT DURATION; BLOOD PRESSURE REGULATION; CORONARY ARTERY DISEASE;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS;

EID: 84888408926     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130332     Document Type: Review

References (160)

1. Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A. and Blasetto, J. W. (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152-160
2. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M., Wun, C. C. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009
3. Horwich, T. B., MacLellan, W. R. and Fonarow, G. C. (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J. Am. Coll. Cardiol. 43, 642-648
4. Foody, J. M., Shah, R., Galusha, D., Masoudi, F. A., Havranek, E. P. and Krumholz, H. M. (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113, 1086-1092
5. Goldberger, J. J., Subacius, H., Schaechter, A., Howard, A., Berger, R., Shalaby, A., Levine, J. and Kadish, A. H. (2006) Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1228-1233
6. Kostis, W. J., Cheng, J. Q., Dobrzynski, J. M., Cabrera, J. and Kostis, J. B. (2012) Meta-analysis of statin effects in women versus men. J. Am. Coll. Cardiol. 59, 572-582
7. Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J., Barnes, E. H., Voysey, M., Gray, A., Collins, R. and Baigent, C. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581-590
8. Zhou, Q. and Liao, J. K. (2010) Pleiotropic effects of statins:basic research and clinical perspectives. Circ. J. 74, 818-826
9. Liao, J. K. and Laufs, U. (2005) Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118
10. Sadowitz, B., Maier, K. G. and Gahtan, V. (2010) Basic science review: Statin therapy - Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc. Endovasc. Surg. 44, 241-251
11. Barandier, C., Ming, X. F. and Yang, Z. (2003) Small G proteins as novel therapeutic targets in cardiovascular medicine. News Physiol. Sci. 18, 18-22
12. Gregg, D., Rauscher, F. M. and Goldschmidt-Clermont, P. J. (2003) Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am. J. Physiol. Cell Physiol. 285, C723-C734
13. Eto, M., Barandier, C., Rathgeb, L., Kozai, T., Joch, H., Yang, Z. and Lüscher, T. F. (2001) Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ. Res. 89, 583-590
14. Callera, G. E., Tostes, R. C., Yogi, A., Montezano, A. C. and Touyz, R. M. (2006) Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin. Sci. 110, 243-253
15. Calo, L. A. and Pessina, A. C. (2007) RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J. Hypertens. 25, 259-264
16. Ichiki, T., Takeda, K., Tokunou, T., Iino, N., Egashira, K., Shimokawa, H., Hirano, K., Kanaide, H. and Takeshita, A. (2001) Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21, 1896-1901
17. Ohtsu, H., Suzuki, H., Nakashima, H., Dhobale, S., Frank, G. D., Motley, E. D. and Eguchi, S. (2006) Angiotensin II signal transduction through small GTP-binding proteins. Hypertension 48, 534-540
18. Chan, S. H. and Chan, J. Y. (2013) Angiotensin-generated reactive oxygen species in brain and pathogenesis of cardiovascular diseases. Antioxid. Redox Signaling 19, 1074-1084
19. Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C. and Walsh, K. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004-1010
20. Pelat, M., Dessy, C., Massion, P., Desager, J. P., Feron, O. and Balligand, J. L. (2003) Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 107, 2480-2486
21. Bonetti, P. O., Lerman, L. O., Napoli, C. and Lerman, A. (2003) Statin effects beyond lipid lowering: are they clinically relevant? Eur. Heart J. 24, 225-248
22. Kishi, T., Hirooka, Y., Kimura, Y., Ito, K., Shimokawa, H. and Takeshita, A. (2004) Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109, 2357-2362
23. Tai, M. H., Wang, L. L., Wu, K. L. and Chan, J. Y. (2005) Increased superoxide anion in rostral ventrolateral medulla contributes to hypertension in spontaneously hypertensive rats via interactions with nitric oxide. Free Radical Biol. Med. 38, 450-462
24. Nagae, A., Fujita, M., Kawarazaki, H., Matsui, H., Ando, K. and Fujita, T. (2009) Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation 119, 978-986
25. Kishi, T. and Hirooka, Y. (2012) Oxidative stress in the brain causes hypertension via sympathoexcitation. Front. Physiol. 3, 335
26. Hirooka, Y., Shigematsu, H., Kishi, T., Kimura, Y., Ueta, Y. and Takeshita, A. (2003) Reduced nitric oxide synthase in the brainstem contributes to enhanced sympathetic drive in rats with heart failure. J. Cardiovasc. Pharmacol. 42, S111-S115
27. Biancardi, V. C., Son, S. J., Sonner, P. M., Zheng, H., Patel, K. P. and Stern, J. E. (2011) Contribution of central nervous system endothelial nitric oxide synthase to neurohumoral activation in heart failure rats. Hypertension 58, 454-463
28. Chan, S. H., Tai, M. H., Li, C. Y. and Chan, J. Y. (2006) Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. Free Radical Biol. Med. 40, 2028-2039
29. Garthwaite, J. and Boulton, C. L. (1995) Nitric oxide signaling in the central nervous system. Annu. Rev. Physiol. 57, 683-706
30. Vaziri, N. D., Ni, Z., Oveisi, F., Liang, K. and Pandian, R. (2002) Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 39, 135-141
31. Nishihara, M., Hirooka, Y., Matsukawa, R., Kishi, T. and Sunagawa, K. (2012) Oxidative stress in the rostral ventrolateral medulla modulates excitatory and inhibitory inputs in spontaneously hypertensive rats. J. Hypertens. 30, 97-106
32. Dampney, R. A. (1994) Functional organization of central pathways regulating the cardiovascular system. Physiol. Rev. 74, 323-364
33. Kishi, T., Hirooka, Y., Ito, K., Sakai, K., Shimokawa, H. and Takeshita, A. (2002) Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Hypertension 39, 264-268
34. Shinohara, K., Hirooka, Y., Kishi, T. and Sunagawa, K. (2012) Reduction of nitric oxide-mediated γ -amino butyric acid release in rostral ventrolateral medulla is involved in superoxide-induced sympathoexcitation of hypertensive rats. Circ. J. 76, 2814-2821
35. Zimmerman, M. C., Lazartigues, E., Lang, J. A., Sinnayah, P., Ahmad, I. M., Spitz, D. R. and Davisson, R. L. (2002) Superoxide mediates the actions of angiotensin II in the central nervous system. Circ. Res. 91, 1038-1045
36. Zhang, Z. H., Yu, Y., Kang, Y. M., Wei, S. G. and Felder, R. B. (2008) Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am. J. Physiol. Heart Circ. Physiol. 294, H1067-H1074
37. Kishi, T. and Hirooka, Y. (2012) Central mechanisms of abnormal sympathoexcitation in chronic heart failure. Cardiol. Res. Pract. 2012, 847172
38. Liu, J. L. and Zucker, I. H. (1999) Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ. Res. 84, 417-423
39. Zhang, W., Huang, B. S. and Leenen, F. H. (1999) Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Am. J. Physiol. 276, H1608-H1615
40. Eshima, K., Hirooka, Y., Shigematsu, H., Matsuo, I., Koike, G., Sakai, K. and Takeshita, A. (2000) Angiotensin in the nucleus tractus solitarii contributes to neurogenic hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 36, 259-263
41. Francis, J., Weiss, R. M., Wei, S. G., Johnson, A. K., Beltz, T. G., Zimmerman, K. and Felder, R. B. (2001) Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am. J. Physiol. Heart Circ. Physiol. 281, H2241-H2251
42. Francis, J., Zhang, Z. H., Weiss, R. M. and Felder, R. B. (2004) Neural regulation of the proinflammatory cytokine response to acute myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 287, H791-H797
43. Zhang, Z. H., Yu, Y., Wei, S. G. and Felder, R. B. (2012) Aldosterone-induced brain MAPK signaling and sympathetic excitation are angiotensin II type-1 receptor dependent. Am. J. Physiol. Heart Circ. Physiol. 302, H742-H751
44. Yu, Y., Zhang, Z. H., Wei, S. G., Serrats, J., Weiss, R. M. and Felder, R. B. (2010) Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension 55, 652-659
45. Zhang, Z. H., Yu, Y., Wei, S. G. and Felder, R. B. (2010) Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling. J. Hypertens. 28, 806-816
46. Fujita, M., Ando, K., Nagae, A. and Fujita, T. (2007) Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in salt sensitive hypertension. Hypertension 50, 360-367
47. Kishi, T., Hirooka, Y., Sakai, K., Shigematsu, H., Shimokawa, H. and Takeshita, A. (2001) Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension 38, 896-901
48. Togashi, H., Sakuma, I., Yoshioka, M., Kobayashi, T., Yasuda, H., Kitabatake, A., Saito, H., Gross, S. S. and Levi, R. (1992) A central nervous system action of nitric oxide in blood pressure regulation. J. Pharmacol. Exp. Ther. 262, 343-347
49. Zhang, K., Mayhan, W. G. and Patel, K. P. (1997) Nitric oxide within the paraventricular nucleus mediates changes in renal sympathetic nerve activity. Am. J. Physiol. 273, R864-R872
50. Endres, M. and Laufs, U. (2004) Effects of statins on endothelium and signaling mechanisms. Stroke 35, 2708-2711
51. Gao, L., Wang, W. and Zucker, I. H. (2008) Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J. Pharmacol. Exp. Ther. 326, 278-285
52. Schlaich, M. P., Kaye, D. M., Lambert, E., Sommerville, M., Socratous, F. and Esler, M. D. (2003) Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108, 560-565
53. Hijmering, M. L., Stroes, E. S., Olijhoek, J., Hutten, B. A., Blankestijn, P. J. and Rabelink, T. J. (2002) Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J. Am. Coll. Cardiol. 39, 683-688
54. Lind, L., Granstam, S. O. and Millgård, J. (2000) Endothelium-dependent vasodilation in hypertension: a review. Blood Pressure 9, 4-15
55. Morgantini, C., Stea, F., Boldrini, B., Duranti, E., Ghiadoni, L. and Natali, A. (2012) Effect of mild hyperinsulinemia on conduit vessel endothelial function: role of noradrenergic activation. J. Hypertens. 30, 720-724
56. Masuo, K., Mikami, H., Ogihara, T. and Tuck, M. L. (1997) Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am. J. Hypertens. 10, 77-83
57. Grassi, G., Dell'Oro, R., Facchini, A., Quarti Trevano, F., Bolla, G. B. and Mancia, G. (2004) Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J. Hypertens. 22, 2363-2369
58. Zipes, D. P. and Rubart, M. (2006) Neural modulation of cardiac arrhythmias and sudden cardiac death. Heart Rhythm 3, 108-113
59. Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B. and Rector, T. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311, 819-823
60. La Rovere, M. T., Pinna, G. D., Hohnloser, S. H., Marcus, F. I., Mortara, A., Nohara, R., Bigger, Jr, J. T., Camm, A. J. and Schwartz, P. J. (2001) Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 103, 2072-2077
61. Barretto, A. C., Santos, A. C., Munhoz, R., Rondon, M. U., Franco, F. G., Trombetta, I. C., Roveda, F., de Matos, L. N., Braga, A. M., Middlekauff, H. R. and Negrão, C. E. (2009) Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int. J. Cardiol. 135, 302-307
62. Hamelin, B. A. and Turgeon, J. (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19, 26-37
63. Matsuki, A., Nozawa, T., Igarashi, N., Sobajima, M., Ohori, T., Suzuki, T., Fujii, N., Igawa, A. and Inoue, H. (2010) Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ. J. 74, 468-475
64. Chirumamilla, A. and Travin, M. I. (2011) Cardiac applications of 123I-mIBG imaging. Semin. Nucl. Med. 41, 374-387
65. Silva, R. J., Bernardes, N., Brito Jde, O., Sanches, I. C., Irigoyen, M. C. and De Angelis, K. (2011) Simvastatin-induced cardiac autonomic control improvement in fructose-fed female rats. Clinics 66, 1793-1796
66. Kishi, T., Hirooka, Y., Mukai, Y., Shimokawa, H. and Takeshita, A. (2003) Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J. Hypertens. 21, 379-386
67. Kishi, T., Hirooka, Y., Shimokawa, H., Takeshita, A. and Sunagawa, K. (2008) Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Clin. Exp. Hypertens. 30, 3-11
68. Kishi, T., Hirooka, Y., Konno, S. and Sunagawa, K. (2009) Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP. Clin. Exp. Hypertens. 31, 698-704
69. Kishi, T. and Sunagawa, K. (2012) Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats. Circ. J. 76, 1934-1941
70. Huang, B. S. and Leenen, F. H. (2003) Sympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 42, 153-160
71. Hirooka, Y., Kimura, Y., Nozoe, M., Sagara, Y., Ito, K. and Sunagawa, K. (2006) Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. Hypertens. Res. 29, 49-56
72. Nozoe, M., Hirooka, Y., Koga, Y., Araki, S., Konno, S., Kishi, T., Ide, T. and Sunagawa, K. (2008) Mitochondria-derived reactive oxygen species mediate sympathoexcitation induced by angiotensin II in the rostral ventrolateral medulla. J. Hypertens. 26, 2176-2184
73. Kishi, T., Hirooka, Y., Konno, S. and Sunagawa, K. (2010) Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 55, 184-190
74. Herring, N., Lee, C. W., Sunderland, N., Wright, K. and Paterson, D. J. (2011) Pravastatin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat. J. Mol. Cell. Cardiol. 50, 99-106
75. Lee, T. M., Lin, M. S. and Chang, N. C. (2007) Effect of pravastatin on sympathetic reinnervation in postinfarcted rats. Am. J. Physiol. Heart Circ. Physiol. 293, H3617-H3626
76. Pliquett, R. U., Cornish, K. G., Peuler, J. D. and Zucker, I. H. (2003) Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107, 2493-2498
77. Pliquett, R. U., Cornish, K. G. and Zucker, I. H. (2003) Statin therapy restores sympathovagal balance in experimental heart failure. J. Appl. Physiol. 95, 700-704
78. Gao, L., Wang, W., Li, Y. L., Schultz, H. D., Liu, D., Cornish, K. G. and Zucker, I. H. (2005) Simvastatin therapy normalizes sympathetic neural control in experimental heart failure. Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 112, 1763-1770
79. Haack, K. K., Gao, L., Schiller, A. M., Curry, P. L., Pellegrino, P. R. and Zucker, I. H. (2013) Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure. Hypertension 61, 723-729
80. Parveen, A., Babbar, R., Agarwal, S., Kotwani, A. and Fahim, M. (2012) Terminalia arjuna enhances baroreflex sensitivity and myocardial function in isoproterenol-induced chronic heart failure rats. J. Cardiovasc. Pharmacol. Ther. 17, 199-207
81. Kishi, T., Hirooka, Y., Kimura, Y., Sakai, K., Ito, K., Shimokawa, H. and Takeshita, A. (2003) Overexpression of eNOS in RVLM improves impaired baroreflex control of heart rate in SHRSP. Hypertension 41, 255-260
82. Wang, Y., Patel, K. P., Cornish, K. G., Channon, K. M. and Zucker, I. H. (2003) nNOS gene transfer to RVLM improves baroreflex function in rats with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 285, H1660-H1667
83. Greer, J. J., Kakkar, A. K., Elrod, J. W., Watson, L. J., Jones, S. P. and Lefer, D. J. (2006) Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. 291, H2743-H2751
84. Melenovsky, V., Wichterle, D., Simek, J., Malik, J., Haas, T., Ceska, R. and Malik, M. (2003) Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. Am. J. Cardiol. 92, 337-341
85. Patterson, D., Dick, J. B. and Struthers, A. D. (2002) Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins? Heart 88, 415-416
86. Cole, C. R., Blackstone, E. H., Pashkow, F. J., Snader, C. E. and Lauer, M. S. (1999) Heart-rate recovery immediately after exercise as a predictor of mortality. N. Engl. J. Med. 341, 1351-1357
87. Tekin, G., Tekin, A., Canatar, T., Sipahi, I., Unsal, A., Katircibaşi, T., Koçum, T., Erol, T., Yiǧit, F., Demircan, S. et al. (2006) Simvastatin improves the attenuated heart rate recovery of type 2 diabetics. Pharmacol. Res. 54, 442-446
88. Dǒgru, M. T., Başar, M. M., Simşek, A., Yuvanç, E., Güneri, M., Ebinç, H. and Batislam, E. (2008) Effects of statin treatment on serum sex steroids levels and autonomic and erectile function. Urology 71, 703-707
89. Kim, S. H., Kim, M. K., Lee, H. Y., Kang, H. J., Kim, Y. J. and Kim, H. S. (2011) Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia:lipoprotein profiles and heart rate variability. Eur. J. Clin. Nutr. 65, 110-116
90. Welzig, C. M., Shin, D. G., Park, H. J., Kim, Y. J., Saul, J. P. and Galper, J. B. (2003) Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Gαi2, a possible molecular marker for parasympathetic responsiveness. Circulation 108, 2743-2746
91. Sínski, M., Lewandowski, J., Ciarka, A., Bidiuk, J., Abramczyk, P., Dobosiewicz, A. and Gaciong, Z. (2009) Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol. Pol. 67, 613-620
92. Lewandowski, J., Sínski, M., Bidiuk, J., Abramczyk, P., Dobosiewicz, A., Ciarka, A. and Gaciong, Z. (2010) Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens. Res. 33, 1038-1043
93. Gomes, M. E., Tack, C. J., Verheugt, F. W., Smits, P. and Lenders, J. W. (2010) Sympathoinhibition by atorvastatin in hypertensive patients. Circ. J. 74, 2622-2626
94. McGowan, C. L., Murai, H., Millar, P. J., Notarius, C. F., Morris, B. L. and Floras, J. S. (2013) Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension. Heart 99, 240-246
95. Pehlivanidis, A. N., Athyros, V. G., Demitriadis, D. S., Papageorgiou, A. A., Bouloukos, V. J. and Kontopoulos, A. G. (2001) Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 157, 463-469
96. Szramka, M., Harriss, L., Ninnio, D., Windebank, E., Brack, J., Skiba, M. and Krum, H. (2007) The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int. J. Cardiol. 117, 287-291
97. Riahi, S., Christensen, J. H., Toft, E., Skou, H. A. and Schmidt, E. B. (2002) HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol. Res. 45, 479-483
98. Riahi, S., Schmidt, E. B., Amanavicius, N., Karmisholt, J., Jensen, H. S., Christoffersen, R. P., Niebuhr, U., Christensen, J. H. and Toft, E. (2006) The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. Int. J. Cardiol. 111, 436-441
99. Riahi, S., Schmidt, E. B., Christensen, J. H., Heath, F., Pedersen, A. K., Nielsen, J. C., Mølgaard, H. and Toft, E. (2005) Statins, ventricular arrhythmias and heart rate variability in patients with implantable cardioverter defibrillators and coronary heart disease. Cardiology 104, 210-214
100. Siddiqi, L., Joles, J. A., Oey, P. L. and Blankestijn, P. J. (2011) Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J. Hypertens. 29, 2176-2180
101. Siddiqi, L., Oey, P. L. and Blankestijn, P. J. (2011) Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol. Dial. Transplant. 26, 2930-2934
102. Narsipur, S. S., Srinivasan, B. and Singh, B. (2011) Effect of simvastatin use on autonomic function in patients with end stage renal disease. Cardiovasc. Hematol. Disord. Drug Targets 11, 53-57
103. Gomes, M. E., Lenders, J. W., Bellersen, L., Verheugt, F. W., Smits, P. and Tack, C. J. (2010) Sympathoinhibitory effect of statins in chronic heart failure. Clin. Auton. Res. 20, 73-78
104. Horwich, T. B., Middlekauff, H. R., Maclellan, W. R. and Fonarow, G. C. (2011) Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J. Card. Failure 17, 879-886
105. Deo, S. H., Fisher, J. P., Vianna, L. C., Kim, A., Chockalingam, A., Zimmerman, M. C., Zucker, I. H. and Fadel, P. J. (2012) Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am. J. Physiol. Heart Circ. Physiol. 303, H377-H385
106. Vrtovec, B., Okrajsek, R., Golicnik, A., Ferjan, M., Starc, V. and Radovancevic, B. (2005) Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J. Card. Failure 11, 684-690
107. Hamaad, A., Sosin, M., Lip, G. Y. and MacFadyen, R. J. (2005) Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc. Drugs Ther. 19, 183-187
108. Notarius, C. F., Butler, G. C., Ando, S., Pollard, M. J., Senn, B. L. and Floras, J. S. (1999) Dissociation between microneurographic and heart rate variability estimates of sympathetic tone in normal subjects and patients with heart failure. Clin. Sci. 96, 557-565
109. Galinier, M., Pathak, A., Fourcade, J., Androdias, C., Curnier, D., Varnous, S., Boveda, S., Massabuau, P., Fauvel, M., Senard, J. M. and Bounhoure, J. P. (2000) Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur. Heart J. 21, 475-482
110. Katircibasi, M. T., Canatar, T., Kocum, H. T., Erol, T., Tekin, G., Demircan, S., Tekin, A., Sezgin, A. T., Baltali, M. and Muderrisoglu, H. (2005) Decreased heart rate recovery in patients with heart failure: effect of fluvastatin therapy. Int. Heart J. 46, 845-854
111. Bleske, B. E., Nicklas, J. M., Bard, R. L., Brook, R. D., Gurbel, P. A., Bliden, K. P., Rajagopalan, S. and Pitt, B. (2006) Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J. Am. Coll. Cardiol. 47, 338-341
112. Gentlesk, P. J., Wiley, T. and Taylor, A. J. (2005) A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am. Heart J. 150, 478-483
113. Tsutamoto, T., Sakai, H., Ibe, K., Yamaji, M., Kawahara, C., Nakae, I., Fujii, M., Yamamoto, T. and Horie, M. (2011) Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ. J. 75, 2160-2166
114. Patel, A. D. and Iskandrian, A. E. (2002) MIBG imaging. J. Nucl. Cardiol. 9, 75-94
115. Rickards, C. A., Ryan, K. L. and Convertino, V. A. (2010) Characterization of common measures of heart period variability in healthy human subjects: implications for patient monitoring. J. Clin. Monit. Comput. 24, 61-70
116. Notarius, C. F. and Floras, J. S. (2001) Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure. Europace 3, 29-38
117. Mortara, A., La Rovere, M. T., Pinna, G. D., Maestri, R., Capomolla, S. and Cobelli, F. (2000) Nonselective β-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J. Am. Coll. Cardiol. 36, 1612-1618
118. Aronson, D. and Burger, A. J. (2001) Effect of β-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure. Ann. Noninvasive Electrocardiol. 6, 98-106
119. Feringa, H. H., Schouten, O., Karagiannis, S. E., Brugts, J., Elhendy, A., Boersma, E., Vidakovic, R., van Sambeek, M. R., Noordzij, P. G., Bax, J. J. and Poldermans, D. (2007) Intensity of statin therapy in relation to myocardial ischemia, troponin T release, and clinical cardiac outcome in patients undergoing major vascular surgery. J. Am. Coll. Cardiol. 50, 1649-1656
120. Zoccali, C., Seravalle, G. and Grassi, G. (2011) Sympathoinhibitory effects of statins in chronic kidney disease:are they clinically relevant? J. Hypertens. 29, 2064-2067
121. Golomb, B. A., Dimsdale, J. E., White, H. L., Ritchie, J. B. and Criqui, M. H. (2008) Reduction in blood pressure with statins:results from the UCSD Statin Study, a randomized trial. Arch. Intern. Med. 168, 721-727
122. Strazzullo, P., Kerry, S. M., Barbato, A., Versiero, M., D'Elia, L. and Cappuccio, F. P. (2007) Do statins reduce blood pressure?:a meta-analysis of randomized, controlled trials. Hypertension 49, 792-798
123. Briasoulis, A., Agarwal, V., Valachis, A. and Messerli, F. H. (2013) Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J. Clin. Hypertens. 15, 310-320
124. Milionis, H. J., Liberopoulos, E. N., Achimastos, A., Elisaf, M. S. and Mikhailidis, D. P. (2006) Statins: another class of antihypertensive agents? J. Hum. Hypertens. 20, 320-335
125. Jamerson, K. A., Julius, S., Gudbrandsson, T., Andersson, O. and Brant, D. O. (1993) Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21, 618-623
126. Giorda, C., Appendino, M., Mason, M. G., Imperiale, E. and Pagano, G. (1995) α1-Blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metab., Clin. Exp. 44, 673-676
127. Gomes, M. E., Mulder, A., Bellersen, L., Verheugt, F. W., Smits, P. and Tack, C. J. (2010) α-Receptor blockade improves muscle perfusion and glucose uptake in heart failure. Eur. J. Heart Failure 12, 1061-1066
128. Haenni, A. and Lithell, H. (1999) Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J. Hypertens. 17, S29-S35
129. Chazova, I., Almazov, V. A. and Shlyakhto, E. (2006) Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes. Metab. 8, 456-465
130. Derosa, G., Cicero, A. F., D'Angelo, A., Fogari, E., Salvadeo, S., Gravina, A., Ferrari, I., Fassi, R. and Fogari, R. (2007) Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Clin. Ther. 29, 602-610
131. Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R., McMurray, J. J., Freeman, D. J., Jukema, J. W. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742
132. Florian, J. P. and Pawelczyk, J. A. (2009) Non-esterified fatty acids increase arterial pressure via central sympathetic activation in humans. Clin. Sci. 118, 61-69
133. Florian, J. P. and Pawelczyk, J. A. (2010) Sympathetic and haemodynamic responses to lipids in healthy human ageing. Exp. Physiol. 95, 486-497
134. Grimm, Jr, R. H. (1989) α1-Antagonists in the treatment of hypertension. Hypertension 13, I131-I136
135. Weidmann, P., Schohn, D. C., Riesen, W., Jahn, H. A., Ferrari, P., Shaw, S. G. and Beretta-Piccoli, C. (1990) Association between sympathetic activity and the atherogenic serum cholesterol fraction. Klin. Wochenschr. 68, 269-276
136. Christensen, J. H., Toft, E., Christensen, M. S. and Schmidt, E. B. (1999) Heart rate variability and plasma lipids in men with and without ischaemic heart disease. Atherosclerosis 145, 181-186
137. Kaplan, N. M. (2003) Morning surge in blood pressure. Circulation 107, 1347
138. Martin, C. A., Cameron, J. D., Head, G. A., Chen, S. S., Eikelis, N. and McGrath, B. P. (2013) The morning blood pressure surge is related to serum cholesterol. J. Hum. Hypertens. 27, 315-320
139. Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P. et al. (2007) Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261
140. Tavazzi, L., Maggioni, A. P., Marchioli, R., Barlera, S., Franzosi, M. G., Latini, R., Lucci, D., Nicolosi, G. L., Porcu, M. and Tognoni, G. (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231-1239
141. Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D. W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C. et al. (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407
142. Takano, H., Mizuma, H., Kuwabara, Y., Sato, Y., Shindo, S., Kotooka, N., Fujimatsu, D., Kobayashi, Y., Inoue, T., Node, K. and Komuro, I. (2013) Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ. J. 77, 917-925
143. Ruzicka, M., Floras, J. S., McReynolds, A. J., Coletta, E., Haddad, H., Davies, R. and Leenen, F. H. (2013) Do high doses of AT1-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure? Clin. Sci. 124, 589-595
144. Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R. and Bernini, F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413-428
145. Horwich, T. B., Hamilton, M. A., Maclellan, W. R. and Fonarow, G. C. (2002) Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Failure 8, 216-224
146. Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. and Anker, S. D. (2003) The relationship between cholesterol and survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 1933-1940
147. Mikus, C. R., Boyle, L. J., Borengasser, S. J., Oberlin, D. J., Naples, S. P., Fletcher, J., Meers, G. M., Ruebel, M., Laughlin, M. H., Dellsperger, K. C. et al. (2013) Simvastatin impairs exercise training adaptations. J. Am. Coll. Cardiol. 62, 709-714
148. Myers, J., Prakash, M., Froelicher, V., Do, D., Partington, S. and Atwood, J. E. (2002) Exercise capacity and mortality among men referred for exercise testing. N. Engl. J. Med. 346, 793-801
149. Kokkinos, P., Myers, J., Faselis, C., Panagiotakos, D. B., Doumas, M., Pittaras, A., Manolis, A., Kokkinos, J. P., Karasik, P., Greenberg, M. et al. (2010) Exercise capacity and mortality in older men: a 20-year follow-up study. Circulation 122, 790-797
150. Huikuri, H. V., Valkama, J. O., Airaksinen, K. E., Seppänen, T., Kessler, K. M., Takkunen, J. T. and Myerburg, R. J. (1993) Frequency domain measures of heart rate variability before the onset of nonsustained and sustained ventricular tachycardia in patients with coronary artery disease. Circulation 87, 1220-1228
151. La Rovere, M. T., Pinna, G. D., Maestri, R., Mortara, A., Capomolla, S., Febo, O., Ferrari, R., Franchini, M., Gnemmi, M., Opasich, C. et al. (2003) Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 107, 565-570
152. The Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389
153. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357
154. Rahimi, K., Majoni, W., Merhi, A. and Emberson, J. (2012) Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. Eur. Heart J. 33, 1571-1581
155. Wanahita, N., Chen, J., Bangalore, S., Shah, K., Rachko, M., Coleman, C. I. and Schweitzer, P. (2012) The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. Am. J. Ther. 19, 16-23
156. Buber, J., Goldenberg, I., Moss, A. J., Wang, P. J., McNitt, S., Hall, W. J., Eldar, M., Barsheshet, A. and Shechter, M. (2012) Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J. Am. Coll. Cardiol. 60, 749-755
157. Fang, W. T., Li, H. J., Zhang, H. and Jiang, S. (2012) The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br. J. Clin. Pharmacol. 74, 744-756
158. Rahimi, K., Emberson, J., McGale, P., Majoni, W., Merhi, A., Asselbergs, F. W., Krane, V. and Macfarlane, P. W. (2011) Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 342, d1250
159. Galiwango, P. J., McReynolds, A., Ivanov, J., Chan, C. T. and Floras, J. S. (2011) Activity with ambulation attenuates diuretic responsiveness in chronic heart failure. J. Card. Failure 17, 797-803
160. Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H. and Braunwald, E. (2006) Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 47, 2326-2331